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ABSTRACT
Objective To evaluate the performance of a rapid test for
chlamydia with first void male urine samples as a
potential tool for diagnosis and screening of chlamydial
infection in men.
Design Evaluation of test performance in prospective
cohort study.
Settings A young people’s sexual health centre (site 1)
and a genitourinary medicine clinic (site 2) in the United
Kingdom.
Participants1211menaged16-73attendingeitherofthe
two sites.
Main outcome measures Sensitivity, specificity, positive
predictive value, and negative predictive value of the
Chlamydia Rapid Test versus polymerase chain reaction
assay. Relation between the visual signal of the
Chlamydia Rapid Test and organism load.
Results Detection rates for Chlamydia trachomatis
infection with polymerase chain reaction were 4.4% (20/
454) at site 1 and 11.9% (90/757) at site 2. Compared
with polymerase chain reaction assay, the resolved
sensitivity, specificity, positive predictive value, and
negativepredictivevalueoftheChlamydiaRapidTestwas
82.6% (90/109), 98.5% (1085/1102), 84.1% (90/107),
and98.3%(1085/1104),respectively.Theorganismload
in first void urine samples that were positive for
chlamydia ranged from 7.28×10
2 to 6.93×10
6 plasmids/
mlandcorrelatedsignificantlywiththevisualsignalofthe
Chlamydia Rapid Test (r=0.7897, P<0.001).
Conclusions The performance of the new Chlamydia
Rapid Test with first void male urine samples indicates
thatitwouldbeaneffectivediagnostictoolforchlamydial
infection in men. The availability of test results within an
hour allows for immediate treatment and contact tracing,
potentially reducing the risks of persistent infection and
onward transmission. The test could also provide a
simple and reliable alternative to nucleic acid
amplification assays for testing of male urine in
chlamydial screening programmes in high prevalence
settings.
INTRODUCTION
Chlamydia trachomatis infection is the most common
sexually transmitted bacterial infection in the United
States and United Kingdom. In the US in 2006, the
number of cases of genital C trachomatis infection
reported to the Centers for Disease Control and Pre-
vention exceeded one million for the first time.
1 This
numberhasincreasedannuallyformorethantwodec-
ades, probably because of a combination of a true
increase in prevalence, more widespread screening,
the availability of more sensitive tests, and more com-
plete national reporting. In the UK, the number of
diagnoses of uncomplicated chlamydial infection in
genitourinary medicine clinics has also climbed stea-
dily since the mid-1990s. Between 2005 and 2006, it
increased by 4% (from 109418 to 113585), with the
number remaining stable in women but increasing by
8% in men.
2
Chlamydial infection is commonly asymptomatic
andremainsunderdiagnosed.Effortsaimedatpromot-
ing safer sexual behaviours and at detecting and treat-
ing infected individuals, especially young adult men,
are therefore important to reduce transmission to sex-
ual partners.
3 Chlamydial infection is most common
among sexually active men and women aged under
25.
14In 2006, the overall rate of reported chlamydial
infection in the US among women was almost three
times that among men, reflecting the larger number
of women screened.
1 With the growing availability of
urine testing, however, men are increasingly being
tested for chlamydial infection.
1 Recent evidence hint-
ing at a causative role for chlamydial infection in male
subfertility might also encourage increased uptake of
testing in men.
56 More widespread and systematic
male testing could substantially reduce the infective
pool,hencepreventingtransmissiontofemalepartners
and reducing serious complications such as pelvic
inflammatory disease, chronic pelvic pain, infertility,
and ectopic pregnancy.
Giventhatthecollectionofurethralswabsisuncom-
fortable for the patient and must be performed by a
trained clinician, screening for chlamydial infection
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performs adequately on urine samples or less painful
meatal swabs. Furthermore, the availability of a high
performance,rapid,andsimpletousetestwouldallow
the implementation of a test and treat regimen,
whereby patients are treated on site during the initial
visit.Theuseofrapidtestscanresultinthetreatmentof
more infected individuals than the use of nucleic acid
amplification tests if the return rate is less than 65%.
7
Nucleicacidamplificationtestsarecommonlyusedfor
chlamydial diagnosis and are more sensitive than
enzyme immunoassay based tests. Nucleic acid ampli-
fication tests, however, take hours or days (if re-testing
isrequired)tocompleteandarecostly.Whileresultsof
laboratory based tests usually take many days to reach
the clinics, currently available rapid tests for the detec-
tion of chlamydia in male urine lack the required sen-
sitivity, even when used in a test and treat setting.
8
We have evaluated the performance of a new Chla-
mydia Rapid Test, developed at the diagnostics devel-
opmentunitoftheUniversityofCambridge.Theassay
isusedinconjunctionwithacollectiondeviceformale
urine(FirstBurst),
910specificallydesignedtocollectthe
firstvoidedurinethatcontainsahigherorganismload,
and test results are available in less than an hour. This
assay was developed to aid in the diagnosis of chlamy-
dial infection and to provide a screening tool for the
detection of such infection among young sexually
active males.
METHODS
Sites
The evaluation sites comprised a young people’s sex-
ual health centre (Brook in Birmingham, site 1) and a
genitourinary medicine clinic (Ambrose King Centre
in London, site 2). Participants were recruited from
March to November 2007.
Participants
All men attending the two sites were invitedto join the
study. They were eligible for enrolment if they were
aged at least 16, had not taken antibiotics in the pre-
vious month, and were able to understand the written
information forms for the study. Each participant
received an information sheet about the study. Partici-
pants gave written informed consent and were then
interviewed confidentially about their symptoms and
relevant sexual history. Participants at site 2 also filled
in a written questionnaire concerning sample collec-
tion methods and preferences after they had provided
a sample.
Specimen collection
Each participant provided two urine samples, the first
one collected using a FirstBurst urine collection
device
9 that collects the first 4-5 ml of urine. Following
the manufacturers’ instructions (Roche and Gen-
Probe), the second urine specimen was collected with
a collection cup routinely used in sexually transmitted
disease clinics in the UK at least two hours after the
FirstBurst specimen was collected. Although not ran-
domised, a previous study showed that the order of
collection did not significantly affect the organism
load in specimens collected by urine cup and tested
with the polymerase chain reaction assay.
9 Each parti-
cipantwasshownanillustratedinstructionsheetdetail-
ing collection of urine with the FirstBurst device.
The second urine sample was divided into two por-
tions, one for polymerase chain reaction testing by an
independent laboratory and the other for freezing and
storage in case we needed to test discordant samples
with the transcription mediated amplification assay.
All urine specimens were handled and stored accord-
ing to the recommendations of the relevant test manu-
facturers.
An independent clinical laboratory evaluated the
reproducibility of the Chlamydia Rapid Test in a study
usingtheguidelineoftheNationalCommitteeonClin-
ical Laboratory Standards.
11 Two operators tested in
duplicate a panel consisting of 10 randomised masked
samples over a period of five days according to the
procedure for the Chlamydia Rapid Test.
Testing with the Chlamydia Rapid Test
Clinic staff tested urine samples on site, with all staff
having passed tester’s requirements in accordance
with the National Committee on Clinical Laboratory
Standards.
11A3mlportionoftheFirstBursturinesam-
ple was diluted with 6 ml of deionised water in a cen-
trifuge tube and then centrifuged at 3000 g for
20minutesatroomtemperature.Occasionallyweper-
formed batch centrifugation of up to 16 specimens/
run. The resulting supernatant was discarded and the
pellet was subjected to extraction by the sequential
addition of 400 µl of reagent 1, 300 µl of reagent 2,
and 100 µl of reagent 3, with mixing between addi-
tions. We then added 100 µl of the extracted sample
to a tube containing lyophilised amplification and
detection reagents. The resulting mixture was gently
Eligible participants (n=1277)
Site 1
Enrolled (n=465), PCR positive=4.4%
Tested by CRT on site and by PCR
at independent laboratory (n=454)
Site 2
Enrolled (n=812), PCR positive=11.9%
Tested by CRT on site and by PCR
at independent laboratory (n=766)
FirstBurst urine, cup urine FirstBurst urine, cup urine
Withdrew (n=5)
Incomplete specimen set (n=38)
Specimen collection protocol not
  followed (n=3)
Invalidated sample (n=9):
  CRT not done (n=5)
  Testing protocol not followed (n=4)
Valid
samples
(n=757)
Invalidated sample (n=0) Valid
samples
(n=454)
Withdrew (n=2)
Incomplete specimen set (n=9)
Fig 1 | Recruitment and testing algorithm for study participants. PCR=polymerase chain
reaction, CRT=Chlamydia Rapid Test
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which we added the test strip to the solution and
allowed it to stand for 25 minutes before reading the
result.Theteststripcontainsamonoclonalantibodyto
chlamydial lipopolysaccharide
12 at the test line and
includes a separate procedural control line. The
appearance of a result line on the test strip indicated
the presence of chlamydia, which was further graded
with a semi-quantitative in-house grading card.
Testing with polymerase chain reaction and transcription
mediated amplification
The performance of the Chlamydia Rapid Test was
assessed to meet the requirements for Conformité
Européenne licensure, which stipulate that the com-
parator test should be a “state of the art” assay and
should be performed with specimens approved for
the test. Polymerase chain reaction testing for chlamy-
dia, which is licensed for urine specimens, was chosen
as the ideal standard test for the study. The Roche
Amplicor CT/NG polymerase chain reaction assay
has undergone comprehensive evaluations with male
urine samples and is similar in reliability to other
nucleic acid amplification methods for detection of C
trachomatis in urine.
13
Urine specimens were sent to a laboratory accre-
dited by the Clinical Pathology Accreditation (UK)
for C trachomatis testing with the Amplicor CT/NG
polymerase chain reaction assay according to manu-
facturer’s instructions (Roche Diagnostic Systems,
Branchburg, NJ). Samples that yielded discordant
results with the Chlamydia Rapid Test and the poly-
merase chain reaction assay were tested with the
mono-specificAptimaCTkit,atranscriptionmediated
amplification assay (Gen-Probe, San Diego, CA)
according to manufacturer’s instructions at the Sexu-
ally Transmitted Bacteria Reference Laboratory
(Health Protection Agency, Colindale). In addition,
100 randomly selected specimens negative with poly-
merasechainreactionand20concordantpositivesam-
ples were masked and tested by this latter assay to
minimise potential bias introduced by testing discor-
dant samples only.
Quantification of organism load
Real time quantitative polymerase chain reaction ana-
lysis was performed as described previously
14 but with
modifications.
15 A portion (500 µl) of the FirstBurst
urinesamplefrommenwithpositiveresultswithpoly-
merase chain reaction was centrifuged at 17860 g for
15 minutes at 25°C and the resulting pellet processed
asdescribedpreviously.
15A20µlportionofeachDNA
extract was used for quantitative polymerase chain
reaction analysis. Estimation of organism load was
determined from a reference curve constructed with a
calibrated plasmid pCTL12A preparation (provided
by I Clarke).
Statistical analysis
Standard statistical methods were used to analyse data
withSASV9.1software(SAS,Cary,NC).APvalueof
<0.05 was considered significant.
RESULTS
Participants and sites
Of 1277 eligible participants at two clinical sites, 1211
contributed usable samples for this study. The sample
size was based on an average prevalence of 10% and a
sensitivity rate of 85%. With 120 positive results, this
would mean less than 7% margin of error for our esti-
mates.
Of the 66 excluded participants, 47 had incomplete
specimen sets, seven withdrew, and the rest were
excluded because of deviations from testing protocol.
Themeanageforthe1211menwhotookpartwas18.2
(range 16.0-25.0) at site 1 and 29.8 (16.5-73.4) at site 2
(P<0.001, unequal variance t test (Satterthwaite)). Fig-
ure 1 shows the recruitment and testing algorithm for
the study participants at both clinical sites. Most parti-
cipants at site 1 attended the sexual health centre for
contraception and other reproductive health services
and were asymptomatic. In contrast, 62% (467/749)
of the participants at site 2 (genitourinary medicine
clinic)presentedwithsymptomsthatincludedurethral
discharge(155/741,21%)anddysuria(169/744,23%).
In addition, 3% (20/757) of the participants at site 2
attended the clinics after being identified through con-
tacttracing.Ofthese20patients,30%(6/20)wereposi-
tiveforchlamydiawithpolymerasechainreactionand
25% (5/20) were positive with the rapid test.
Reproducibility of testing with the Chlamydia Rapid Test
There was a concordance of 100% between the
expected results and the results generated from rando-
mised and masked panels by two independent opera-
tors performing the Chlamydia Rapid Test.
Table 1 |Unresolved and resolved* performance with Chlamydia Rapid Test versus polymerase chain reaction. Figures are percentages (numbers) (binomial
95% exact confidence intervals)
Site
Sensitivity (%) Specificity (%) Positive predictive value Negative predictive value
Unresolved Resolved Unresolved Resolved Unresolved Resolved Unresolved Resolved
1( n =454) 90.0 (18/20)
(68.3 to 98.8)
90.0 (18/20)
(68.3 to 98.8)
98.2 (426/434)
(96.4 to 99.2)
98.2 (426/434)
(96.4 to 99.2)
69.2 (18/26)
(48.2 to 85.7)
69.2 (18/26)
(48.2 to 85.7)
99.5 (426/428)
(98.3 to 99.9)
99.5 (426/428)
(98.3 to 99.9)
2( n =757) 80.0 (72/90)
(70.2 to 87.7)
80.9 (72/89)
(71.2 to 88.5)
98.7 (658/667)
(97.4 to 99.4)
98.7 (659/668)
(97.5 to 99.4)
88.9 (72/81)
(80.0 to 94.8)
88.9 (72/81)
(80.0 to 94.8)
97.3 (658/676)
(95.8 to 98.4)
97.5 (659/676)
(96.0 to 98.5)
Total
(n=1211)
81.8 (90/110)
(73.3 to 88.5)
82.6 (90/109)
(74.1 to 89.2)
98.5 (1084/1101)
(97.5 to 99.1)
98.5 (1085/1102)
(97.5 to 99.1)
84.1 (90/107)
(75.8 to 90.5)
84.1 (90/107)
(75.8 to 90.5)
98.2 (1084/1104)
(97.2 to 98.9)
98.3 (1085/1104)
(97.3 to 99.0)
*All resolved values calculated from data on testing of discrepant samples.
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TheChlamydiaRapidTestwasperformedonurinecol-
lectedwiththeFirstBurstdevice,whilethepolymerase
chain reaction was performed on urine collected with
the standard cup. Positivity rates with polymerase
chain reaction assay were 4% (20/454) at site 1 and
12% (90/757) at site 2. The combined unresolved sen-
sitivity and specificity of the Chlamydia RapidTest was
81.8% and 98.5%, respectively (table 1). After the
Sexually Transmitted Bacteria Reference Laboratory
tested discordant samples, the Chlamydia Rapid Test
had a combined overall sensitivity and specificity of
82.6% and 98.5% (table 1). All 100 randomly selected
concordant negative samples (100%, 95% confidence
interval 96.38% to 100%) and 19/20 (75.13% to
99.87%) concordant positive samples were confirmed
by the transcription mediated amplification assay
(exact confidence interval calculated with the Monte
Carlo exact method of estimation). When we took the
resultsofthelimitedconcordanttestingintoconsidera-
tion, the imputed sensitivity, specificity, positive pre-
dictivevalue,and negativepredictivevalue was81.9%
(range 54.0-82.6%), 98.1% (96.4-98.5%), 80.4% (63.6-
84.1%), and 98.3% (94.8-98.3%), respectively. The
ranges in brackets are the extreme scenarios, using
boththelowerandupper95%confidenceintervalesti-
mates for positive and negative concordance in our
imputation.
TheChlamydiaRapidTesthadoverallresolvedposi-
tiveandnegativepredictivevaluesof84.1%and98.3%
(table 1). There were significant differences in the
negative (P=0.009) and positive (P=0.028) predictive
values of the Chlamydia Rapid Test between the two
sites, although the 95% confidence intervals over-
lapped slightly for the positive predictive values.
Furthermore, the likelihood ratio for a positive result
fromtheChlamydiaRapidTestsuggeststhatforthelow
prevalence site (site 1), a positive result modifies the
odds of chlamydia by 50:1, while in the higher preva-
lence site (site 2), the likelihood modifies it by 61:5
(table 2). In contrast, a negative result from the test
modifies the original odds of chlamydia in site 1 by
0.102 to 1, and in site 2, by 0.185 to 1. Taking into
accounttheresultsfromlimitednumberofconcordant
positive and negative samplestested, the adjustedlike-
lihood ratios for a positive and a negative result for the
combined sites were 43.1 (range 15.0-55.1) and 0.184
(0.177-0.477), respectively.
Chlamydia Rapid Test in asymptomatic patients
At the time of recruitment to the study, 90% (18/20) of
men positive for chlamydia with polymerase chain
reaction from site 1 and 31% (28/90) from site 2 had
no genitourinary symptoms. Of these asymptomatic
men, 89% (16/18) and 71% (20/28), respectively, had
positive results with the Chlamydia Rapid Test, giving
anoveralltestsensitivityforasymptomaticmenof78%
(36/46).Withsymptomaticmenwhowere positivefor
chlamydia, there was a higher combined sensitivity
(84%, 54/64) at both sites.
Organism load in men positive with polymerase chain
reaction
AftertheChlamydiaRapidTesttherewasenoughurine
left from the FirstBurst sample to determine organism
load in 80/90 men positive with polymerase chain
reaction at site 2. We analysed the DNA extracted
from these urine specimens with quantitative poly-
merase chain reaction assay with a primer set that
amplifies a highly conserved sequence of the 7.5-kb
cryptic plasmid of C trachomatis. The organism load
for these samples ranged from 7.28×10
2 to 6.93×10
6
plasmids/ml of urine. The visual signal of the Chlamy-
dia Rapid Test was significantly correlated (r=0.7897,
P<0.001) with C trachomatis load (fig 2).
Acceptability of FirstBurst device and waiting time for
result
After specimens had been collected from the men in
site 2, each participant was offered a written question-
naire. The response rate was 95% (767/812), although
some of the returned questionnaires were not filled in
completely, with the result that the total number of
answers for each question varied slightly. Some 98%
(741/759) of respondents found the instructions easy
to understand, and 97% (735/755) found collection of
theirurineeasy.Withregardtopreferences,89%(619/
697) of respondents preferred to give a urine sample,
7% (49/697) would have preferred to give a urethral
swab, and 4% (29/697) were willing to provide either
sample. Participants were not asked to give a urethral
swab so for those men who had not experienced ure-
thralswabbingtheirexpressedpreferencemightnotbe
valid. As to preference for a urine collector, 76% (525/
687) of respondents preferred the FirstBurst device,
Table 2 |Positive and negative likelihood ratio for test results with Chlamydia Rapid Test
Site
Positive Negative
Unresolved Resolved Unresolved Resolved
1( n =454) 50.0 50.0 0.102 0.102
2( n =757) 61.5 62.2 0.202 0.193
Total (n=1211) 54.5 55.1 0.185 0.177
Organism load (plasmids/ml)
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Fig 2 | Correlation between Ct r a c h o m a t i sorganism load
determined with quantitative polymerase chain reaction
analysis and visual signal of Chlamydia Rapid Test for 80
urine specimens positive with polymerase chain reaction
(r=0.7897, P<0.001)
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remaining 6% (38/687) were willing to use either
device. With regard to waiting time for the test result,
96%(653/683)ofrespondentsindicatedthattheywere
willing to wait an hour or more and 4% (30/683) indi-
cated that they would not wait more than an hour.
DISCUSSION
Clinical performance of the new Chlamydia Rapid Test
The Chlamydia Rapid Test is suitable for diagnosis of
chlamydial infection in men because of its high sensi-
tivity and specificity. This new test provides same day
results, allowing for immediate treatment of infected
patients. The Chlamydia Rapid Test evaluated here
for use with male urine is a modified version of that
previously evaluated for use with vaginal swabs,
wherein a similar performance (83.5% resolved sensi-
tivity and 98.9% specificity) was observed.
16 Its appli-
cationtorapidchlamydiatestingmightenhanceefforts
to target asymptomatic men and facilitate both the
treatment and contact tracing of infected individuals.
TheChlamydiaRapidTestexaminedwasdeveloped
for the detection of C trachomatis infection in men with
the use of first void urine as sample. C trachomatis
infects the urethral mucosa in men, and this tissue is
usually sampled either with urethral swabs or first
void urine. The participants in our study preferred
urine samples because of the discomfort associated
with swab collection. We recently showed that the
chlamydial load in first void urine does not differ sig-
nificantlyfromthatofurethralswabs.
15Tofacilitatethe
reliable collection of the first void urine samples, we
used a new urine collection device (FirstBurst), which
is provided with the Chlamydia Rapid Test kit. The
urine sample collected with this device contains a
load of C trachomatis up to six times that in specimens
collected with a regular urine cup, thereby increasing
thesensitivityofthetest.
9Theorderofdifferentcollec-
tion methods did not significantly affect the organism
load of the specimens of urine collected in cups tested
with polymerase chain reaction.
9
The evaluated Chlamydia Rapid Test incorporates a
novel signal amplification system that has proved
effective in enhancing the performance of this test.
1216
The level of sensitivity achieved by the Chlamydia
RapidTestinthisstudyisunprecedentedforanimmu-
noassay based rapid test, as previously developed
rapid tests for Chlamydia have shown poor sensitivity
with cup collected male urine when compared with
nucleic acid amplification tests.
8 For example, using
Ligase chain reaction as a comparison test, Clearview
Chlamydia (Unipath, now Inverness) had a sensitivity
and specificity of 67.7% and 95.5%, respectively, Test-
pack Chlamydia (Abbott) had 70.9% and 95.5%, and
Surecell Chlamydia (Kodak) had 62.9% and 100%.
8
The difference in performance with the previous
rapid tests might in part be related to the FirstBurst
sample collection.
The Chlamydia Rapid Test showed an overall unre-
solved sensitivity of 81.8% and a positive predictive
value of 84.1%. At the young people’s sexual health
centre (site 1), where the prevalence of chlamydial
infection was only 4.4%, the positive predictive value
of the Chlamydia Rapid Test was significantly lower
(69.2 v 88.9%) than that at the genitourinary medicine
clinic (site 2), where the prevalence of infection was
11.9%, although there was a slight overlap in the 95%
confidence intervals for the two sites. This finding is
not unexpected because of the different prevalence
rates at the respective study sites. The Chlamydia
Rapid Test also showed an overall high positive like-
lihood ratio (54.5:1), suggesting that a positive result
multiplies the individual’s original likelihood of chla-
mydia by 54.5:1.
Effortstocontrolchlamydialinfectionamongyoung
sexually active people are unlikely to succeed without
an effective testing programme for men. Given that
men do not get tested for chlamydia as often as
women do, as well as the inevitable delay in obtaining
results with currently available testing methods, men
with asymptomatic chlamydial infection continue to
provide a transmission link for the disease that is
missed by current testing programmes. Prevention of
the spread of disease will thus require a high perfor-
mance rapid test for chlamydia that allows for a test
and treat regimen, in addition to the existing nucleic
acid amplification tests. Emerging concerns regarding
the role ofchlamydiain malesubfertilitymightencou-
rage more asymptomatic men to come forward for
screening.
56
The performance of the Chlamydia Rapid Test is
clearly related to the organism load within the speci-
men.Higherloadshavebeenassociatedwithincreased
chlamydia positivity in tested sexual partners, suggest-
ing that those with higher loads are more infectious.
17
This wasconfirmed in our study,where we observed a
higherpositivityrate(30%withpolymerasechainreac-
tion v 25% with the Chlamydia Rapid Test) in men who
attended because of contact tracing. Men who tested
positive with the Chlamydia Rapid Test are thus likely
to be the most infectious, and rapid removal of these
infected men from the reservoir of infection with a test
and treat regimen mighthave an advantage over tradi-
tional screening approaches. This hypothesis warrants
further investigation in appropriately designed trials.
Relianceonnucleicacidtestingalonecanbeproble-
matic,dependingonthetargetusedintheassay.Thisis
evidencedbytherecentdemonstrationofthepresence
of the Swedish C trachomatis variant with partial dele-
tionofplasmidinmanyEuropeancountries
18aswellas
another distinct variant strain that could not be
detected by plasmid based nucleic acid amplification
tests.
19 These strains would be detectable by the Chla-
mydia RapidTest because the testrecognisesthe genus
specific Chlamydia lipopolysaccharide.
In developing countries, the availability of the Chla-
mydia Rapid Test would also allow more men to be
screened and treated. Specific diagnostic tests for chla-
mydia are rarely available in these regions and man-
agement is often based on self reportedsymptoms and
clinical signs, thus missing asymptomatic men alto-
gether. Given the high prevalence of chlamydial
RESEARCH
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20 male
customersare likely to transmitinfection totheir other
sexualpartnersandshouldthereforebeamongthepri-
mary targets for chlamydia testing.
Strengths and weaknesses of the study
This study included two centres with relatively large
population sizes at sites with low and high prevalence.
Weusedconfirmatorytestingondiscordantsamplesto
resolve true chlamydial positivity and additional ran-
dom testing to minimise the bias from “selective” ana-
lysisofdiscordantsamples.Inaddition,therewashigh
reproducibility of testing between operators, strength-
eningthevalidityofthelaboratorymethods.TheChla-
mydia Rapid Test specimens were collected from men
whohadnothadtoholdtheirurinefortwohours,thus
providing applicability in a real world setting without
the time restrictions imposed by traditional testing
algorithms.
The number of men positive for chlamydia at site 1
was low because of the low prevalence nature of this
site.The95%confidence intervalsforthesensitivityof
the Chlamydia Rapid Test were larger at site 1 than at
site2.Also,inthedeterminationofchlamydiaload,the
reference curve was based on purified plasmid pre-
parations in buffer, therefore we could not control for
inhibitorysubstancespotentiallypresentinsomeurine
specimens.
Future research
Future studies should focus on determining whether
the widespread use of the Chlamydia Rapid Test in
screening young men for chlamydial infection in high
prevalence settings can help prevent sequelae among
their female sexual partners. In addition, more studies
are warranted to verify whether the Chlamydia Rapid
Test would reassure young men that testing can be
quick, simple, and non-invasive, and this might
increase uptake. The rapid test might also be used to
confirmthechlamydiastatusinmenwithsymptomatic
non-gonococcal urethritis at the point of care, thus
allowing more efficient contact tracing and focusing
the health promotion resources on these individuals
at the time of testing. Any potential improvement of
the outcome over current approaches with nucleic
acid amplified based screening should be evaluated
in relation to alternative strategies. Finally, to further
reduce the testing time of the rapid test, it might be
worth exploring the use of urethral swab, especially
in genitourinary medicine clinics that routinely collect
urethral smears. This advantage, however, should be
balanced with the fear in men of urethral procedures,
which abounds in genitourinary medicine clinics, not
only among those who have attended previously.
21
Conclusions
The new Chlamydia Rapid Test for urine samples from
men showed high sensitivity and specificity that can
produce results within an hour. It is therefore suitable
as a primary diagnostic tool, especially in settings
where patients need to be tested and treated in one
visit. It could also be used as a screening tool in areas
withahighprevalenceofinfectionor insettingswhere
access to nucleic acid amplification tests is limited or
where the return rate is low. Further studies are
required to determine the utility and cost effectiveness
of the Chlamydia Rapid Test in such roles.
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